This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Erythropoietin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Erythropoietin is a haemopoietic glycoprotein growth factor derived from a single gene on chromosome seven which is expressed in cells of the renal cortex. Some 10% is produced by the liver by unknown cells; this amount is not enough for normal functioning. Its key action is to control erythropoiesis.

Normally erythropoietin is produced as a result hypoxia detected by an oxygen sensor; it then acts back on an effector receptor. There is normally a rise in levels in anaemia.

Recombinant erythropoietin is clinically useful in a range of conditions including chronic renal failure. It must be grown in mammalian cell lines so that proper glycosylation can occur.

Notes:

  • there are concerns about using erythopoietin in patients with cancer:
    • study evidence revealed that erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of venous thromboembolism (VTE) and mortality (1)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.